Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:BMY

Bristol Myers Squibb (BMY)

66.58
-0.37 (0.55%)
as of Aug 28, 2026, 8:00:00 pm Market Open.
162 watching
0
Investor Insights
star iconAug 30, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

Bristol Myers Squibb (BMY) has garnered a mixed set of opinions from various analysts. Some reviewers highlight the company's strong performance in 2023, with a 19% increase in stock price and a robust free cash flow projected to hit $15 billion by 2027. The company is also noted for its attractive dividend yield exceeding 4% and a promising drug pipeline, which could support future growth. However, concerns have been raised regarding the disappointing sales of its Cobenfy drug, leading some experts to reassess their investment positions. Overall, there is a sense of cautious optimism about the potential for recovery if the growth portfolio can continue to outperform the legacy products.

consensus icon
Consensus
Mixed
valuation icon
Valuation
Undervalued
review icon
Similar
EliLilly,LLY
DON'T BUY
Doesn't expect much growth, plus there are some issues.
DON'T BUY
New drug failed and generic drug companies getting into their products. Market share will probably shrink.
TOP PICK
Decent upside potential. Close to a decent technical support. Relatively cheap.
PAST TOP PICK
(Was a top pick on Apr 4 down 11%) Still likes.
DON'T BUY
Very reasonable valuation. Patents are coming off. Prefers Pfizer.
TOP PICK
Has had some negative occurances. At a good price.
BUY
18 X next years earnings makes it very attractive.
TOP PICK
(Was a top pick on Dec 17 up 15%) At a historic low.
DON'T BUY
Broke through a technical base. Generics are giving some tough competition.
TOP PICK
Restructured. In a temporary downturn.
BUY
Good upside potential.
DON'T BUY
Not a fan at this time. Patent expiries coming up. Prefers Pfizer.
Showing 211 to 222 of 222 entries